

July 11, 2023

Axel Bolte  
President and Chief Executive Officer  
Inozyme Pharma, Inc.  
321 Summer Street, Suite 400  
Boston, MA 02210

Inc.

fiscal year ended December 31, 2022  
2023

Re: Inozyme Pharma,  
Form 10-K for the  
Filed March 22,  
File No. 001-39397

Dear Axel Bolte:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences